Breast Cancer Proteomics and Molecular Heterogeneity

Primary objective: The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes Secondary objective: * To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes. * To relate proteomic findings to survival data * To identify potential serum markers of breast cancer progression

NCT Number	NCT01840293
Lead Sponsor	Cancer Trials Ireland
Conditions	Primary Breast Cancer, Recurrent/Metastatic Breast Cancer
Enrollment	1,780 participants
Start Date	2013-02
Primary Completion	2029-12 (estimated)
Study Completion	2038-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-19